ProfileGDS5678 / 1435874_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 80% 79% 74% 76% 79% 78% 77% 76% 76% 77% 81% 77% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0389276
GSM967853U87-EV human glioblastoma xenograft - Control 25.674980
GSM967854U87-EV human glioblastoma xenograft - Control 35.4661779
GSM967855U87-EV human glioblastoma xenograft - Control 44.9605574
GSM967856U87-EV human glioblastoma xenograft - Control 55.1483376
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3033679
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2350878
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.189477
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1803976
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0942176
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1509777
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8088181
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2204377
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5550679